INBRACE^® Support Program for INGREZZA

Many paths, one goal: Access for every patient prescribed INGREZZA^® (valbenazine) capsules

From prescription fulfillment to financial assistance options and product support, the INBRACE Support Program assists patients and their care partners—so they can focus on treatment goals.

Call 84-INGREZZA (844-647-3992), 8 am to 8 pm ET, Monday through Friday, to learn more.

LEARN MORE TREATMENT FORM

Start your patients on INGREZZA right away

INGREZZA Samples

Provide samples of INGREZZA to start patients on treatment today

CONTACT A REP

Free Trial Offer

Request a free one-month supply of INGREZZA for new patients

The free trial is not contingent on a purchase of any kind. Product dispensed under this free trial program may not be submitted for reimbursement to any third-party payer. We reserve the right to modify or cancel the program at any time. Additional terms and conditions apply.

DOWNLOAD FORM

Most patients pay less than $10 out-of-pocket for INGREZZA¹

Financial assistance options are available to help your patients start and stay on treatment:
$0 copay for INGREZZA for eligible commercial patients who qualify for the INGREZZA Savings Program.

This offer is valid only for patients with commercial (nongovernment-funded) insurance. Additional terms and conditions apply.

ENROLL IN COPAY SAVINGS

No costs for eligible patients through the INGREZZA Patient Assistance Program. No insurance -or- No prescription coverage for INGREZZA

Additional terms and conditions apply.

APPLY FOR ASSISTANCE

Now it’s easier than ever for your patients to access INGREZZA²

>85% of INGREZZA prescriptions fulfilled, regardless of formulary access
<2 weeks on average to dispense and deliver INGREZZA directly to your patients

Dedicated, field-based experts provide you personalized access solutions

Regional Patient Access Managers (R-PAMs) are local experts in INGREZZA access. Whether on-site or over the phone, they are ready to help you and your office staff navigate the pathway to patient access.

CONNECT WITH AN R-PAM

CoverMyMeds^® streamlines the prior authorization (PA) process

CoverMyMeds^® is an electronic prior authorization (ePA) solution that helps patients get the medication they need by streamlining the PA process for providers and pharmacists.

The added service and support of a dedicated network of pharmacies

To help ensure timely access and delivery, INGREZZA is available through a select network of specialty and closed-door pharmacies providing the highest level of service and support to you and your patients.

SEE THE PROCESS

Looking for more access resources?

Download access-related forms and templates to help you and your practice.

DOWNLOAD FORMS

REFERENCES: 1. Data on file as of Q1 2021. Neurocrine Biosciences, Inc. 2. Data on file as of Q4 2020. Neurocrine Biosciences, Inc.

Important Information

INDICATION & USAGE

INGREZZA^® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

WARNINGS & PRECAUTIONS

Somnolence

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Parkinsonism

INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS

The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see INGREZZA full Prescribing Information

See full Important Safety Information

Important Information

INDICATION & USAGE

INGREZZA^® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

WARNINGS & PRECAUTIONS

Somnolence

QT Prolongation

Parkinsonism

ADVERSE REACTIONS

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see INGREZZA full Prescribing Information

REFERENCES: 1. Data on file as of Q1 2021. Neurocrine Biosciences, Inc. 2. Data on file as of Q4 2020. Neurocrine Biosciences, Inc.

IMPORTANT SAFETY INFORMATION

PRESCRIBING
INFORMATION

Video description

Actor portrayals of tardive dyskinesia movements were completed in the presence of a movement disorder neurologist who assessed each movement for severity from 0 (no dyskinesia) to 4 (severe dyskinesia) using Items 1 through 7 of the Abnormal Involuntary Movement Scale (AIMS).

Subscores for baseline video

AIMS Items 1-4: Facial and oral movements	Baseline	Week 6	Week 48
1. Muscles of facial expression	3	1	0
2. Lips and perioral area	2	2	2
3. Jaw	2	2	2
4. Tongue	0	0	0
AIMS Items 5-6: Extremity movements
5. Upper (arms, wrists, hands, fingers)	2	2	2
6. Lower (legs, knees, ankles, toes)	0	0	0
AIMS Item 7: Trunk movements
7. Neck, shoulders, hips	1	0	0
Total AIMS scores portrayed in video	10	7	6

INBRACE® Support Program for INGREZZA

Many paths, one goal: Access for every patient prescribed INGREZZA® (valbenazine) capsules

Start your patients on INGREZZA right away

INGREZZA Samples

Free Trial Offer

Most patients pay less than $10 out-of-pocket for INGREZZA1

Dedicated, field-based experts provide you personalized access solutions

CoverMyMeds® streamlines the prior authorization (PA) process

The added service and support of a dedicated network of pharmacies

Looking for more access resources?

INDICATION & USAGE

CONTRAINDICATIONS

WARNINGS & PRECAUTIONS

Somnolence

QT Prolongation

Parkinsonism

ADVERSE REACTIONS

Video description

INBRACE^® Support Program for INGREZZA

Many paths, one goal: Access for every patient prescribed INGREZZA^® (valbenazine) capsules

Most patients pay less than $10 out-of-pocket for INGREZZA¹

CoverMyMeds^® streamlines the prior authorization (PA) process